Human herpes simplex virus: Life cycle and development of inhibitors

@article{Kukhanova2014HumanHS,
  title={Human herpes simplex virus: Life cycle and development of inhibitors},
  author={Marina K Kukhanova and Anna N Korovina and Sergey N Kochetkov},
  journal={Biochemistry (Moscow)},
  year={2014},
  volume={79},
  pages={1635-1652}
}
WHO reports that 90% of human population is infected by different types of herpesviruses, which develop latency or cause oral and genital herpes, conjunctivitis, eczema herpeticum, and other diseases. Herpesvirus almost always accompanies HIV-infection and complicates AIDS treatment. Herpes simplex virus type 1 is one of the most wide spread viruses from the Herpesviridae family. HSV virion, genome structure, replication mechanisms, antiherpes drug development strategies, including design of… Expand

Paper Mentions

Interventional Clinical Trial
The objective of this present study was to asses the pharmacokinetic properties of acyclovir tablet from new product formulation (PT. Kimia Farma (Persero) Tbk) to its innovator product… Expand
ConditionsDrug Use
InterventionDrug
Herpesvirus Polymerase Inhibitors
TLDR
HSV virion, genome structure, replication mechanisms, antiherpes drug development strategies, including designing of prodrugs and vaccines are the topic of discussion in this chapter. Expand
Experimental Dissection of the Lytic Replication Cycles of Herpes Simplex Viruses in vitro
TLDR
The lytic replication cycles of herpes simplex viruses are reviewed and dissected, discussing key steps involved in cell infection and the processes that yield new virions to facilitate the identification of the mechanisms of action of anti-HSV compounds. Expand
Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections
TLDR
The lifecycle of HSV-1 as it pertains to corneal infections and the clinically approved as well as emerging treatments to combat HSV1 infections are discussed and some newly identified host targets for the antiviral drug development are highlighted. Expand
Herpesvirus: an underestimated virus
TLDR
This short review proposes to present concisely the history of HSV, its taxonomy, physical structure, and replication and to explore the pathogenesis of the infection, clinical manifestations, laboratory diagnosis, treatment, prophylaxis and epidemiology of the diseases. Expand
Herpes Simplex Virus: Methods and Protocols
TLDR
This book provides protocols currently in use in leading laboratories in many fields of HSV-1 research, covering basic aspects of virus structure, the prevalence of and diseases caused by the virus, replication in cultured cells, viral latency, antiviral defenses, and the mechanisms that the virus uses to counteract these defenses. Expand
Herpes Simplex Virus Establishment, Maintenance, and Reactivation: In Vitro Modeling of Latency
TLDR
Cell culture models that recapitulate latent infection provide valuable insight on the host processes regulating viral establishment and maintenance of latency in herpes simplex viruses. Expand
Tour de Herpes: Cycling Through the Life and Biology of HSV-1.
TLDR
This book provides protocols currently in use in leading laboratories in many fields of HSV-1 research, covering basic aspects of virus structure, the prevalence of and diseases caused by the virus, replication in cultured cells, viral latency, antiviral defenses, and the mechanisms that the virus uses to counteract these defenses. Expand
Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice
TLDR
Ginkgolic acid’s antiviral activity against HSV-1 skin infection in BALB/cJ mice is reported and it is anticipated it to be effective against additional cutaneous and potentially systemic viral infections. Expand
Harringtonine Inhibits Herpes Simplex Virus Type 1 Infection by Reducing Herpes Virus Entry Mediator Expression
TLDR
Harringtonine showed antiviral activity against HSV-1 and ACV-resistant strains by targeting HVEM and could be a promising therapeutic candidate for mitigating HSv-1-induced-pathogenesis. Expand
Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection
TLDR
Currently available anti-herpetic therapies, novel molecules being assessed in clinical trials and new botanical compounds reported in the last 20 years with antiviral activities against HSVs that might represent future treatments against these viruses are reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 175 REFERENCES
Crystal Structure of the Herpes Simplex Virus 1 DNA Polymerase*
TLDR
The first crystal structure of a herpesvirus polymerase is presented, the Herpes Simplex Virus type 1 DNA polymerase, at 2.7 Å resolution and a novel inhibition mechanism is proposed in which a representative of a series of non-nucleosidic viral polymerase inhibitors, the 4-oxo-dihydroquinolines, binds at the polymerase active site interacting non-covalently with both the polymer enzyme and the DNA duplex. Expand
Herpesviruses: latency and reactivation – viral strategies and host response
  • B. Grinde
  • Medicine
  • Journal of oral microbiology
  • 2013
TLDR
The review starts by introducing possible viral strategies in general and the particular biology and host relationship of the various human herpesviruses, including their pathology, are examined subsequently. Expand
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
TLDR
New inhibitors of the HSV helicase-primase with potent in vitro anti-herpes activity, a novel mechanism of action, a low resistance rate and superior efficacy against HSV in animal models are reported. Expand
Antiviral agents for herpes simplex virus.
TLDR
HSV research is emerging from a quiescent phase, with the focus on new approaches and novel compounds, in particular, the combination of ACV with hydrocortisone, known as ME609 or zovirax duo, an HSV helicase-primase inhibitor, pritelivir, and CMX001, the cidofovir prodrug for treating resistant HSV infection in immunocompromised patients. Expand
Famciclovir and Valaciclovir Differ in the Prevention of Herpes Simplex Virus Type 1 Latency in Mice: a Quantitative Study
TLDR
Significantly less latent virus was detected by all four methods, however, in Ganglia obtained from mice that had been treated with FCV in comparison with the amount detected in ganglia from mice That had been treating with VACV, but in no case was latency completely eliminated. Expand
Inhibition of Herpes Simplex Virus by Polyamines
TLDR
Dextran-propan-1,3-diamine (DPD) was found to be the most potent of all the compounds examined and could have an advantage as a topical application in combination therapy of HSV lesions. Expand
Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy.
TLDR
The heterogeneity within the viral populations and the temporal changes of drug-resistant viruses found in this HSCT recipient were remarkable, showing a rapid evolution of HSV-1. Expand
Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes.
TLDR
Drug-resistant herpes simplex virus type 1 recombinant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes were evaluated for their susceptibility to various antivirals in the presence of hydroxyurea (HyU), which can increase the activity of nucleoside/nucleotide analogues against drug-resistant viruses. Expand
Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease
TLDR
These studies validate the use of helicase-primase inhibitors for the treatment of acute herpesvirus infections and provide new lead compounds for optimization and design of superior anti-HSV agents. Expand
Mutations in the DNA polymerase and thymidine kinase genes of herpes simplex virus clinical isolates resistant to antiherpetic drugs
TLDR
The phylogenetic sequence analysis showed that the ul30 and ul23 sequences of clinical isolates were close to those of L2, and that ul30 conserved regions differed between HSV-1 isolates and L2 only in point mutations and degenerated substitutions. Expand
...
1
2
3
4
5
...